Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 210589-09-6
Drug Levels and Effects
Summary of Use during Lactation
Limited information from on mother receiving laronidase for mucopolysaccharidosis type I indicates that the drug is not detectable in breastmilk and her breastfed infant suffered no adverse reactions or adverse developmental effects from the drug in milk. If laronidase is required by the mother, it is not a reason to discontinue breastfeeding. Until more data are available, laronidase should be used with careful monitoring during breastfeeding.
Drug Levels
Maternal Levels. A woman with mucopolysaccharidosis type I received intravenous laronidase 100 units/kg weekly during breastfeeding, beginning one week after delivery. Laronidase was undetectable (assay limits not specified) in breastmilk just before the infusion and 60 minutes after the infusion at 1 and 3 months postpartum.[1]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
A woman with mucopolysaccharidosis type I received intravenous laronidase 100 units/kg weekly for 28 doses during her 37-week pregnancy. She resumed therapy one week after delivery and breastfed her infant for 3 months. The infant had normal height and weight up to 12 months of age and showed normal development at 2.5 years of age. No adverse drug reactions were reported in the infant.[1]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Castorina M, Antuzzi D, Richards SM, et al. Successful pregnancy and breastfeeding in a woman with mucopolysaccharidosis type I while receiving laronidase enzyme replacement. therapy. Clin Exp Obstet Gynecol. 2015;42:108–13. [PubMed: 25864295]
Substance Identification
Substance Name
Laronidase
CAS Registry Number
210589-09-6
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubMedLinks to PubMed
- Review Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.[Cochrane Database Syst Rev. 2016]Review Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.Jameson E, Jones S, Remmington T. Cochrane Database Syst Rev. 2016 Apr 1; 4:CD009354. Epub 2016 Apr 1.
- Review Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.[Cochrane Database Syst Rev. 2013]Review Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.Jameson E, Jones S, Wraith JE. Cochrane Database Syst Rev. 2013 Nov 21; (11):CD009354. Epub 2013 Nov 21.
- Review Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.[Cochrane Database Syst Rev. 2013]Review Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.Jameson E, Jones S, Wraith JE. Cochrane Database Syst Rev. 2013 Sep 26; (9):CD009354. Epub 2013 Sep 26.
- Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series.[Orphanet J Rare Dis. 2016]Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series.Horovitz DD, Acosta AX, Giugliani R, Hlavatá A, Hlavatá K, Tchan MC, Lopes Barth A, Cardoso L Jr, Embiruçu de Araújo Leão EK, Esposito AC, et al. Orphanet J Rare Dis. 2016 Apr 29; 11(1):51. Epub 2016 Apr 29.
- Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.[Cochrane Database Syst Rev. 2019]Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.Jameson E, Jones S, Remmington T. Cochrane Database Syst Rev. 2019 Jun 18; 6(6):CD009354. Epub 2019 Jun 18.
- Laronidase - Drugs and Lactation Database (LactMed®)Laronidase - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...